Strategic steps for moving sterile injectables from lab to clinical trials

The article, sponsored by Vetter, discusses how drug owners of sterile injectable candidates face a key question when a molecule is ready for first‑in‑human studies: how fast can a clinical batch be produced.

While speed is tempting, the piece stresses that the transition from laboratory to clinic requires deliberate decisions that affect manufacturability, regulatory filings, and scale‑up. Partnering with a forward‑thinking contract development and manufacturing organization can provide the strategic foundation needed.

The author outlines four guiding principles, beginning with mapping the sequence of critical choices. For example, the choice of primary packaging determines material requirements, which shape the quality‑by‑design design space, process development, analytical methods, and control strategies, all of which feed into regulatory documentation.

By treating these interrelated decisions as a coordinated roadmap rather than a rushed checklist, companies can improve the robustness of their clinical batches and reduce downstream risks.